51
|
Kang EJ, Kavanaugh A. Psoriatic arthritis: latest treatments and their place in therapy. Ther Adv Chronic Dis 2015; 6:194-203. [PMID: 26137209 DOI: 10.1177/2040622315582354] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
Psoriatic arthritis (PsA) is a heterogeneous chronic inflammatory disease that may affect peripheral and axial joints, entheses, skin and nails, and other organs. Treatment with nonsteroidal anti-inflammatory drugs, steroid and disease-modifying antirheumatic drugs had been the backbone of traditional management of PsA for many years. However, improvement in our understanding of immunopathogenesis of PsA has led to new immunomodulatory therapies. Introduction of novel agents has raised the bar for treatment and helped drive research into additional therapeutic options.
Collapse
Affiliation(s)
- Eun Jin Kang
- Division of Rheumatology, Department of Medicine, Busan Medical Center, Busan, Republic of Korea
| | - Arthur Kavanaugh
- Division of Rheumatology, Allergy, and Immunology, Center for Innovative Therapy, University of California, San Diego, 9500 Gilman Drive, Mail Code 0943, La Jolla, CA 92037, USA
| |
Collapse
|
52
|
Animal models of rheumatoid arthritis: How informative are they? Eur J Pharmacol 2015; 759:278-86. [PMID: 25824900 DOI: 10.1016/j.ejphar.2015.03.047] [Citation(s) in RCA: 69] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2015] [Revised: 03/06/2015] [Accepted: 03/12/2015] [Indexed: 12/19/2022]
Abstract
Animal models of arthritis are widely used to de-convolute disease pathways and to identify novel drug targets and therapeutic approaches. However, the high attrition rates of drugs in Phase II/III rates means that a relatively small number of drugs reach the market, despite showing efficacy in pre-clinical models. There is also increasing awareness of the ethical issues surrounding the use of animal models of disease and it is timely, therefore, to review the relevance and translatability of animal models of arthritis. In this paper we review the most commonly used animal models in terms of their pathological similarities to human rheumatoid arthritis as well as their response to drug therapy. In general, the ability of animal models to predict efficacy of biologics in man has been good. However, the predictive power of animal models for small molecules has been variable, probably because of differences in the levels of target knockdown achievable in vivo.
Collapse
|
53
|
Mazur M, Karczewski J, Lodyga M, Żaba R, Adamski Z. Inhibitors of phosphodiesterase 4 (PDE 4): A new therapeutic option in the treatment of psoriasis vulgaris and psoriatic arthritis. J DERMATOL TREAT 2014; 26:326-8. [PMID: 25424050 DOI: 10.3109/09546634.2014.991267] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Psoriasis vulgaris and psoriatic arthritis are inflammatory diseases in which inflammation and sustained inducing lesions result from immune disorders associated with overactivity of T cells that produce multiple proinflammatory cytokines, including tumor necrosis factor alpha (TNF-α) and interleukin (IL): IL-2, IL-12, IL-17, IL-22 or IL-23. Modern treatment of these diseases is focused on reducing the inflammatory process responsible for the development of the disease. In recent years, the treatment of psoriasis is developing at a dynamic rate. Such therapeutic advances are contributed to the possibility of patient therapy through the use of some registered biologic agents, such as TNF-α inhibitors (infliximab, etanercept and adalimumab), and an inhibitor of the p40 subunit common to IL-12 and IL-23 (ustekinumab). In addition to the already registered medications for the indications mentioned above, there is a large group of preparations that are currently undergoing clinical trials in Europe, Canada and the United States, which provides hopes of therapy efficacy and safety.
Collapse
Affiliation(s)
- Małgorzata Mazur
- Department and Clinic of Dermatology, Karol Marcinkowski University of Medical Sciences , Poznan , Poland
| | | | | | | | | |
Collapse
|
54
|
Ushach I, Burkhardt AM, Martinez C, Hevezi PA, Gerber PA, Buhren BA, Schrumpf H, Valle-Rios R, Vazquez MI, Homey B, Zlotnik A. METEORIN-LIKE is a cytokine associated with barrier tissues and alternatively activated macrophages. Clin Immunol 2014; 156:119-27. [PMID: 25486603 DOI: 10.1016/j.clim.2014.11.006] [Citation(s) in RCA: 81] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2014] [Revised: 11/19/2014] [Accepted: 11/22/2014] [Indexed: 01/16/2023]
Abstract
Cytokines are involved in many functions of the immune system including initiating, amplifying and resolving immune responses. Through bioinformatics analyses of a comprehensive database of gene expression (BIGE: Body Index of Gene Expression) we observed that a small secreted protein encoded by a poorly characterized gene called meteorin-like (METRNL), is highly expressed in mucosal tissues, skin and activated macrophages. Further studies indicate that Metrnl is produced by Alternatively Activated Macrophages (AAM) and M-CSF cultured bone marrow macrophages (M2-like macrophages). In the skin, METRNL is expressed by resting fibroblasts and IFNγ-treated keratinocytes. A screen of human skin-associated diseases showed significant over-expression of METRNL in psoriasis, prurigo nodularis, actinic keratosis and atopic dermatitis. METRNL is also up-regulated in synovial membranes of human rheumatoid arthritis. Taken together, these results indicate that Metrnl represents a novel cytokine, which is likely involved in both innate and acquired immune responses.
Collapse
Affiliation(s)
- Irina Ushach
- Department of Physiology and Biophysics, University of California Irvine, Irvine, CA, USA; Institute for Immunology, University of California Irvine, Irvine, CA, USA
| | - Amanda M Burkhardt
- Department of Physiology and Biophysics, University of California Irvine, Irvine, CA, USA; Institute for Immunology, University of California Irvine, Irvine, CA, USA
| | - Cynthia Martinez
- Department of Dermatology, School of Medicine, University of Duesseldorf, Duesseldorf, Germany
| | - Peter A Hevezi
- Department of Physiology and Biophysics, University of California Irvine, Irvine, CA, USA; Institute for Immunology, University of California Irvine, Irvine, CA, USA
| | - Peter Arne Gerber
- Department of Dermatology, School of Medicine, University of Duesseldorf, Duesseldorf, Germany
| | | | - Holger Schrumpf
- Department of Dermatology, School of Medicine, University of Duesseldorf, Duesseldorf, Germany
| | - Ricardo Valle-Rios
- Department of Physiology and Biophysics, University of California Irvine, Irvine, CA, USA; Institute for Immunology, University of California Irvine, Irvine, CA, USA; Present address: Laboratory of Immunology and Proteomics, Children's Hospital of Mexico, Mexico, D.F. 06720, Mexico
| | - Monica I Vazquez
- Department of Physiology and Biophysics, University of California Irvine, Irvine, CA, USA; Institute for Immunology, University of California Irvine, Irvine, CA, USA
| | - Bernhard Homey
- Department of Dermatology, School of Medicine, University of Duesseldorf, Duesseldorf, Germany
| | - Albert Zlotnik
- Department of Physiology and Biophysics, University of California Irvine, Irvine, CA, USA; Institute for Immunology, University of California Irvine, Irvine, CA, USA.
| |
Collapse
|
55
|
Pleyer U, Stübiger N. New pharmacotherapy options for noninfectious posterior uveitis. Expert Opin Biol Ther 2014; 14:1783-99. [DOI: 10.1517/14712598.2014.956074] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
56
|
Liu JT, Yeh HM, Liu SY, Chen KT. Psoriatic arthritis: Epidemiology, diagnosis, and treatment. World J Orthop 2014; 5:537-543. [PMID: 25232529 PMCID: PMC4133459 DOI: 10.5312/wjo.v5.i4.537] [Citation(s) in RCA: 85] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/24/2013] [Revised: 01/24/2014] [Accepted: 06/18/2014] [Indexed: 02/06/2023] Open
Abstract
Our understanding of psoriatic arthritis has evolved as new knowledge of the disease has emerged. However, the exact prevalence of psoriatic arthritis is unknown, and its pathogenesis has not been fully elucidated. Genetic, environmental, and immunologic factors have all been implicated in disease development. Early diagnosis and treatment have become primary objectives in clinical rheumatology. Psoriatic arthritis not only causes functional impairment, but also increases mortality risk of patients. The advent of new therapeutic agents capable of arresting the progression of joint damage is expected. However, early psoriatic arthritis assessment remains limited. The objectives of this article are to outline the epidemiology, diagnosis, and treatment of psoriatic arthritis and to suggest a paradigm for identifying early psoriatic arthritis patients.
Collapse
|
57
|
Susunaga-Notario ADC, Pérez-Gutiérrez S, Zavala-Sánchez MA, Almanza-Pérez JC, Gutiérrez-Carrillo A, Arrieta-Báez D, López-López AL, Román-Ramos R, Flores-Sáenz JLE, Alarcón-Aguilar FJ. Bioassay-guided chemical study of the anti-inflammatory effect of Senna villosa (Miller) H.S. Irwin & Barneby (Leguminosae) in TPA-induced ear edema. Molecules 2014; 19:10261-78. [PMID: 25029073 PMCID: PMC6271645 DOI: 10.3390/molecules190710261] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2014] [Revised: 07/09/2014] [Accepted: 07/10/2014] [Indexed: 01/15/2023] Open
Abstract
Senna villosa (Miller) is a plant that grows in México. In traditional Mexican medicine, it is used topically to treat skin infections, pustules and eruptions and to heal wounds by scar formation. However, studies of its potential anti-inflammatory effects have not been performed. The aim of the present study was to determine the anti-inflammatory effect of extracts from the leaves of Senna villosa and to perform a bioassay-guided chemical study of the extract with major activity in a model of ear edema induced by 12-O-tetradecanoylphorbol 13-acetate (TPA). The results reveal that the chloroform extract from Senna villosa leaves has anti-inflammatory and anti-proliferative properties. Nine fractions were obtained from the bioassay-guided chemical study, including a white precipitate from fractions 2 and 3. Although none of the nine fractions presented anti-inflammatory activity, the white precipitate exhibited pharmacological activity. It was chemically characterized using mass spectrometry and infrared and nuclear magnetic resonance spectroscopy, resulting in a mixture of three aliphatic esters, which were identified as the principal constituents: hexyl tetradecanoate (C20H40O2), heptyl tetradecanoate (C21H42O2) and octyl tetradecanoate (C22H44O2). This research provides, for the first time, evidence of the anti-inflammatory and anti-proliferative properties of compounds isolated from Senna villosa.
Collapse
Affiliation(s)
- Ana del Carmen Susunaga-Notario
- Doctorado en Biología Experimental, D.C.B.S., Universidad Autónoma Metropolitana, Unidad Iztapalapa, Av. San Rafael Atlixco No.186 Colonia, Vicentina, Iztapalapa 09340, Mexico.
| | - Salud Pérez-Gutiérrez
- Laboratory of Productos Naturales, Departamento Sistemas Biológicos, D.C.B.S., Universidad Autónoma Metropolitana Unidad Xochimilco, Calzada del Hueso 1100, Col, Villa Quietud, Coyoacán 04690, Mexico.
| | - Miguel Angel Zavala-Sánchez
- Laboratory of Productos Naturales, Departamento Sistemas Biológicos, D.C.B.S., Universidad Autónoma Metropolitana Unidad Xochimilco, Calzada del Hueso 1100, Col, Villa Quietud, Coyoacán 04690, Mexico.
| | - Julio Cesar Almanza-Pérez
- Laboratory of Farmacología, Departamento Ciencias de la Salud, D.C.B.S., Universidad Autónoma Metropolitana Unidad Iztapalapa, Av. San Rafael Atlixco No.186 Colonia, Vicentina, Iztapalapa 09340, Mexico.
| | - Atilano Gutiérrez-Carrillo
- Laboratory of RMN, Departamento de Química, D.C.B.I. Universidad Autónoma Metropolitana-Iztapalapa, Av. San Rafael Atlixco No. 186, México D.F. 09340, Mexico.
| | - Daniel Arrieta-Báez
- Instituto Politécnico Nacional-CNMN, Calle, Luis Enrique Erro s/n, Unidad Profesional Adolfo López Mateos, Gustavo A, Madero 07738, Mexico.
| | - Ana Laura López-López
- Doctorado en Biología Experimental, D.C.B.S., Universidad Autónoma Metropolitana, Unidad Iztapalapa, Av. San Rafael Atlixco No.186 Colonia, Vicentina, Iztapalapa 09340, Mexico.
| | - Rubén Román-Ramos
- Laboratory of Farmacología, Departamento Ciencias de la Salud, D.C.B.S., Universidad Autónoma Metropolitana Unidad Iztapalapa, Av. San Rafael Atlixco No.186 Colonia, Vicentina, Iztapalapa 09340, Mexico.
| | - José Luis Eduardo Flores-Sáenz
- Laboratory of Farmacología, Departamento Ciencias de la Salud, D.C.B.S., Universidad Autónoma Metropolitana Unidad Iztapalapa, Av. San Rafael Atlixco No.186 Colonia, Vicentina, Iztapalapa 09340, Mexico.
| | - Francisco Javier Alarcón-Aguilar
- Laboratory of Farmacología, Departamento Ciencias de la Salud, D.C.B.S., Universidad Autónoma Metropolitana Unidad Iztapalapa, Av. San Rafael Atlixco No.186 Colonia, Vicentina, Iztapalapa 09340, Mexico.
| |
Collapse
|
58
|
Cauli A, Porru G, Piga M, Vacca A, Dessole G, Mathieu A. Clinical potential of apremilast in the treatment of psoriatic arthritis. Immunotargets Ther 2014; 3:91-6. [PMID: 27471702 PMCID: PMC4918237 DOI: 10.2147/itt.s40199] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
Abstract
Psoriatic arthritis (PsA) is a frequent chronic inflammatory disease characterized by joint and skin involvement, and by typical extra-articular manifestations. Although the pathogenesis of PsA is still under investigation, the available evidence suggests the importance of the patient’s genetic background, microbial or environmental triggers, and an imbalance in the adaptive and acquired immune system, resulting in the production of inflammatory mediators. New therapeutic approaches have been proposed, among them the use of modulators of intracellular signals and gene transcription such as PDE4-inhibiting compounds, which are able to modulate the activity of transcription factors such as CREB and NF-κB and therefore the synthesis of inflammatory mediators, resulting in immunoregulation. This paper summarizes the mechanism of action of apremilast, a PDE4 inhibitor, and the clinical data available on its clinical efficacy and safety profile in the treatment of PsA patients.
Collapse
Affiliation(s)
- Alberto Cauli
- Rheumatology Unit, Department of Medical Sciences, Policlinico of University of Cagliari, Monserrato, Italy
| | - Giovanni Porru
- Rheumatology Unit, Department of Medical Sciences, Policlinico of University of Cagliari, Monserrato, Italy
| | - Matteo Piga
- Rheumatology Unit, Department of Medical Sciences, Policlinico of University of Cagliari, Monserrato, Italy
| | - Alessandra Vacca
- Rheumatology Unit, Department of Medical Sciences, Policlinico of University of Cagliari, Monserrato, Italy
| | - Grazia Dessole
- Rheumatology Unit, Department of Medical Sciences, Policlinico of University of Cagliari, Monserrato, Italy
| | - Alessandro Mathieu
- Rheumatology Unit, Department of Medical Sciences, Policlinico of University of Cagliari, Monserrato, Italy
| |
Collapse
|
59
|
Bruner V, Atteno M, Spanò A, Scarpa R, Peluso R. Biological therapies for spondyloarthritis. Ther Adv Musculoskelet Dis 2014; 6:92-101. [PMID: 24891880 PMCID: PMC4040940 DOI: 10.1177/1759720x14535512] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
Biological therapies and new imaging techniques have changed the therapeutic and diagnostic approach to spondyloarthritis. In patients with axial spondyloarthritis, tumor necrosis factor α (TNFα) inhibitor treatment is currently the only effective therapy in patients for whom conventional therapy with nonsteroidal anti-inflammatory drugs (NSAIDs) has failed. TNFα inhibitor treatment is more effective in preventing articular damage in peripheral joints than in axial ones. It is important to treat patients at an early stage of disease to reduce disease progression; moreover it is necessary to identify causes of therapy inefficacy in preventing joint damage in the axial subset.
Collapse
Affiliation(s)
- Vincenzo Bruner
- Rheumatology Research Unit, Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy
| | - Mariangela Atteno
- Rheumatology Research Unit, Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy
| | - Angelo Spanò
- Rheumatology Research Unit, Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy
| | - Raffaele Scarpa
- Rheumatology Research Unit, Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy
| | - Rosario Peluso
- Rheumatology Research Unit, Department of Clinical Medicine and Surgery, University Federico II, via Sergio Pansini 5, 80131 Naples, Italy
| |
Collapse
|
60
|
Sheane BJ, Chandran V. Investigational drugs for treating psoriatic arthritis. Expert Opin Investig Drugs 2014; 23:1001-16. [DOI: 10.1517/13543784.2014.910194] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Affiliation(s)
- Barry J Sheane
- University of Toronto Psoriatic Arthritis Clinic, Centre for Prognosis Studies in the Rheumatic Diseases, University Health Network, Toronto Western Hospital,
1E 416, 399 Bathurst Street, Toronto, Ontario, M5T 2S8, Canada ;
- University of Toronto, Department of Medicine, Division of Rheumatology,
Toronto, Canada
| | - Vinod Chandran
- University of Toronto Psoriatic Arthritis Clinic, Centre for Prognosis Studies in the Rheumatic Diseases, University Health Network, Toronto Western Hospital,
1E 416, 399 Bathurst Street, Toronto, Ontario, M5T 2S8, Canada ;
- University of Toronto, Department of Medicine, Division of Rheumatology,
Toronto, Canada
| |
Collapse
|
61
|
Varada S, Tintle SJ, Gottlieb AB. Apremilast for the treatment of psoriatic arthritis. Expert Rev Clin Pharmacol 2014; 7:239-50. [DOI: 10.1586/17512433.2014.904200] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
62
|
Abstract
This article explores the current and emerging therapies for skin disease, with a particular focus on chronic plaque psoriasis and metastatic malignant melanoma. We discuss the current biological therapies used for psoriasis and those on the horizon, including small molecules and biosimilars. We also summarise the recent advances in the use of novel therapeutic agents in other dermatological diseases and outline the promise of translational research and stratified medicine approaches in dermatology. Better matching of patients with therapies is anticipated to have a major effect on both clinical practice and the development of new drugs and diagnostics.
Collapse
Affiliation(s)
- Arif Aslam
- Dermatology Centre, Salford Royal NHS Foundation Trust, University of Manchester, Manchester, UK
| | - Christopher EM Griffiths
- Dermatology Centre, Salford Royal NHS Foundation Trust, University of Manchester, Manchester, UK
| |
Collapse
|
63
|
Lynch M, Kirby B, Warren RB. Treating moderate to severe psoriasis – best use of biologics. Expert Rev Clin Immunol 2013; 10:269-79. [DOI: 10.1586/1744666x.2014.873701] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
|